Position in SCYX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$168,994
-$135,627 QoQ
Shares Held
41,522
-0.0% QoQ
Ownership
0.417%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#18
of 39 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SCYX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $21,635,633,053 across 65 Drug Manufacturers - Specialty & Generic names. SCYX ranks #50 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
5,294,529 | $2,868,734,637 | |
| 2 | ZTS |
Zoetis Inc.
|
39,430,181 | $2,833,452,797 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
13,711,607 | $2,310,954,234 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
63,894,301 | $2,164,738,910 | |
| 5 | ALKS |
Alkermes plc.
|
29,235,739 | $1,531,952,715 | |
| 6 | VTRS |
Viatris Inc
|
86,019,468 | $1,365,989,144 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
48,849,973 | $1,202,197,829 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
28,703,514 | $995,150,823 |
All Filings in SCYX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $168,994 | 41,522 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $304,621 | 332,194 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $211,497 | 334,648 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $257,678 | 334,648 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $225,887 | 334,648 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $402,048 | 422,322 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $515,718 | 426,214 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $634,207 | 425,643 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||